The eyes in diabetes and diabetes through the eyes

[1]  Seppo Lehto,et al.  Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women , 2007, Diabetes Care.

[2]  R. Klein,et al.  Severe Hypoglycemia and Smoking in a Long-Term Type 1 Diabetic Population , 2007, Diabetes Care.

[3]  G. Lang.  Pharmacological Treatment of Diabetic Retinopathy , 2007, Ophthalmologica.

[4]  T. Wong,et al.  Obesity and eye diseases. , 2007, Survey of ophthalmology.

[5]  H. Helbig.  Surgery for Diabetic Retinopathy , 2007, Ophthalmologica.

[6]  A. Neubauer,et al.  Laser Treatment in Diabetic Retinopathy , 2007, Ophthalmologica.

[7]  Allen C Clermont,et al.  Retinal Blood Flow in Diabetes , 2007, Microcirculation.

[8]  M. Larsen,et al.  Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. , 2006, Acta ophthalmologica Scandinavica.

[9]  I. Idris,et al.  Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy. , 2006, Diabetes & vascular disease research.

[10]  G. Werther,et al.  The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. , 2006, Current medicinal chemistry.

[11]  M. Larsen,et al.  Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. , 2006, Acta ophthalmologica Scandinavica.

[12]  A. P. Hall.  Review of the Pericyte during Angiogenesis and its Role in Cancer and Diabetic Retinopathy , 2006, Toxicologic pathology.

[13]  T. Ianchulev,et al.  Role of vascular endothelial growth factor in ocular angiogenesis. , 2006, Ophthalmology clinics of North America.

[14]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[15]  Kristian Klemp,et al.  The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. , 2005, Investigative ophthalmology & visual science.

[16]  H. Parving,et al.  The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics , 2005, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[17]  A. Vaag,et al.  Effect of short-term hyperglycemia on multifocal electroretinogram in diabetic patients without retinopathy. , 2004, Investigative ophthalmology & visual science.

[18]  Vishali Gupta,et al.  Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. , 2004, American journal of ophthalmology.

[19]  L. Aiello,et al.  Retinopathy in diabetes. , 2004, Diabetes care.

[20]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[21]  T. Chowdhury,et al.  The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? , 2002, Eye.

[22]  Lawrence A. Yannuzzi,et al.  PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.

[23]  R. Pandey,et al.  Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. , 2002, Diabetes research and clinical practice.

[24]  P. Fernlund,et al.  Progression of retinopathy in insulin-treated type 2 diabetic patients. , 2002, Diabetes care.

[25]  J. Reichert-Thoen,et al.  Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy , 2002, Diabetologia.

[26]  A. Albert,et al.  Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. , 2001, Diabetes care.

[27]  A. Liebl,et al.  [Costs of type 2 diabetes in Germany. Results of the CODE-2 study]. , 2001, Deutsche medizinische Wochenschrift.

[28]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[29]  A. Liebl,et al.  Kosten des Typ-2-Diabetes in Deutschland , 2001 .

[30]  S. Chakrabarti,et al.  Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy , 2000, Diabetes/metabolism research and reviews.

[31]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[32]  C. Puliafito,et al.  Optical coherence tomography after laser photocoagulation for clinically significant macular edema. , 2000, Ophthalmic surgery and lasers.

[33]  Matthew D. Davis,et al.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.

[34]  M. Inami,et al.  Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein. , 1998, American journal of ophthalmology.

[35]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. , 1998, Ophthalmology.

[36]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[37]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[38]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[39]  F. Ferris,et al.  Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. , 1998, Investigative ophthalmology & visual science.

[40]  A. Sjølie,et al.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.

[41]  B. Hoogwerf,et al.  Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. , 1996, Archives of ophthalmology.

[42]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. , 1995, Ophthalmology.

[43]  J. Finlayson,et al.  High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. , 1994, Investigative ophthalmology & visual science.

[44]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[45]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.

[46]  H. Yamashita,et al.  Effect of rapid glycemic control on progression of diabetic retinopathy. , 1992, Japanese journal of ophthalmology.

[47]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. , 1991, Ophthalmology.

[48]  D L DeMets,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VI. Retinal photocoagulation. , 1987, Ophthalmology.

[49]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. , 1984, Archives of ophthalmology.

[50]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.